Illumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 299,361 shares of the life sciences company’s stock after selling 12,818 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Illumina were worth $28,430,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Assetmark Inc. lifted its holdings in shares of Illumina by 10.2% in the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the last quarter. Versant Capital Management Inc grew its stake in Illumina by 8.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after buying an additional 111 shares during the last quarter. Archer Investment Corp grew its stake in Illumina by 12.9% during the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after buying an additional 123 shares during the last quarter. Callan Family Office LLC increased its position in Illumina by 4.4% during the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after buying an additional 124 shares during the period. Finally, Parallel Advisors LLC lifted its stake in Illumina by 4.7% in the third quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock valued at $269,000 after buying an additional 128 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company’s stock.

Illumina Stock Up 3.0%

Illumina stock opened at $126.59 on Friday. The stock has a 50 day moving average of $131.25 and a two-hundred day moving average of $120.45. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The stock has a market capitalization of $19.36 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 2.35 and a beta of 1.45. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the company posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Expanded Labcorp collaboration to drive NGS adoption, expand distributed testing access, generate evidence for payer coverage and develop new oncology tests—provides a clear commercial growth pathway for Illumina’s oncology sequencing business. Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
• Positive Sentiment: Quarterly / sector commentary highlights Illumina as “firing on all cylinders,” reinforcing that recent earnings and revenue trends support upside in sequencing product and services demand. Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders
• Neutral Sentiment: Analyst fair-value modeling saw only a very small adjustment (from $135.94 to $136.05), signaling modest change to the baseline valuation despite active coverage shifts—mixed views persist across the Street. How The Illumina (ILMN) Story Is Shifting With 2026 Expectations And Mixed Street Views
• Neutral Sentiment: Broader analyst / comparative write-ups and stock-screen coverage (including independent company analyses) are circulating but don’t add a clear directional push—useful for longer-term thesis rather than immediate catalyst. Analyzing Illumina (NASDAQ:ILMN) and CervoMed (NASDAQ:CRVO)
• Negative Sentiment: Some strategists warn that recent share gains may already price in a stronger Q4 and 2026 outlook, which raises the risk of limited near-term upside or a pullback if execution or macro assumptions slip. ILMN Stock Gains Following Expanded Collaboration With Labcorp

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. UBS Group reaffirmed a “neutral” rating and issued a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Barclays upped their price target on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Piper Sandler decreased their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Finally, Evercore set a $150.00 price objective on shares of Illumina in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.